{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(1)"],"submitter":["Hjerpe E"],"pubmed_abstract":["<h4>Background</h4>A deregulated energy metabolism is a hallmark of malignant disease that offers possible future targets for treatment. We investigated the prognostic value of the glycolytic enzymes glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate kinase type M2 (PKM2), mitochondrial β-F1-ATPase (ATP5B) and the bioenergetic cellular (BEC) index in advanced ovarian cancer.<h4>Methods</h4>Fresh tumor samples were prospectively collected from 123 patients undergoing primary surgery for suspected advanced ovarian cancer. Of these, 57 met the eligibility criteria; stage IIC-IV, serous or endometrioid subtype, specimens containing ≥ 50% tumor cells and patients receiving platinum-based chemotherapy. An adequate amount of mRNA could be extracted in all but one case, with a resultant"],"journal":["BMC clinical pathology"],"pagination":["30"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3874631"],"repository":["biostudies-literature"],"pubmed_title":["Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer."],"pmcid":["PMC3874631"],"pubmed_authors":["Carlson J","Johansson H","Egyhazi Brage S","Hjerpe E","Avall-Lundqvist E","Frostvik Stolt M","Shoshan M","Schedvins K"],"additional_accession":[]},"is_claimable":false,"name":"Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer.","description":"<h4>Background</h4>A deregulated energy metabolism is a hallmark of malignant disease that offers possible future targets for treatment. We investigated the prognostic value of the glycolytic enzymes glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and pyruvate kinase type M2 (PKM2), mitochondrial β-F1-ATPase (ATP5B) and the bioenergetic cellular (BEC) index in advanced ovarian cancer.<h4>Methods</h4>Fresh tumor samples were prospectively collected from 123 patients undergoing primary surgery for suspected advanced ovarian cancer. Of these, 57 met the eligibility criteria; stage IIC-IV, serous or endometrioid subtype, specimens containing ≥ 50% tumor cells and patients receiving platinum-based chemotherapy. An adequate amount of mRNA could be extracted in all but one case, with a resultant","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Nov","modification":"2025-04-04T22:17:35.535Z","creation":"2019-03-27T01:19:07Z"},"accession":"S-EPMC3874631","cross_references":{"pubmed":["24252137"],"doi":["10.1186/1472-6890-13-30"]}}